PARIS, Feb. 15, 2005 (PRIMEZONE) -- Stanislaw R. Burzynski, M.D., Ph.D., founder and CEO of the Burzynski Clinic and President of the Burzynski Research Institute, Inc. (OTCBB:BZYR) in Houston, gave a presentation entitled "Targeted Therapy with Antineoplastons A10 and AS2-1 (ANP) of High Grade, Recurrent and Progressive Brain Stem Glioma (HBSG)" to the 16th International Congress on Anti-Cancer Treatment (ICACT) -- February 1-4, 2005.
The objective of Dr. Burzynski's presentation was to describe an evaluation of the outcome for patients diagnosed with HBSG, including glioblastoma multiforme and treated with ANP in four Phase II clinical trials -- testing the hypothesis that ANP treatment yields longer survival and a greater number of objective responses than current standard therapy.
A10 and AS2-1 (ANP), which Dr. Burzynski and his team developed in the 1990's, are synthetic derivatives of glutamine, isoglutamine and phenylacetic acid. These agents have been found to work as molecular switches that may turn on tumor suppressor genes and turn off oncogenes.
Dr. Burzynski believes that research results in patients receiving ANP therapy lead to the following conclusions:
-- Greater than a 5-year survival rate in a small group of
HBSG patients.
-- Longer progression free survival responses than patients
undergoing standard therapy.
-- Longer overall survival than patients undergoing standard
therapy.
-- Higher positive response rate than those receiving standard
therapy.
-- ANP is well tolerated -- with rare, sporadic and reversible
adverse drug reactions.
Prior to this presentation, Dr. Burzynski was a featured speaker at the Cleveland Clinic's Annual Brain Tumor Symposium, Neuro-Oncology 2005, held in Orlando, Florida, January 29-31, 2005.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. BRI cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1. BRI does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
The Burzynski Research Institute logo can be found at: http://www.primezone.com/newsroom/prs/?pkgid=1291